Morgan Stanley reissued their overweight rating on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a research ...

The General Confederation of Moroccan Enterprises (CGEM) urged the government Monday to continue its reforms aimed at boosting private investment, particularly in small and medium enterprises (SMEs).

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has been given a consensus rating of “Buy” by the eight research firms that are covering the firm, MarketBeat.com reports.

Morgan Stanley assumed coverage of Cullinan Therapeutics (CGEM) with an Overweight rating and a price target of $35, down from $38. The firm ...

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of ...

Stay updated on market trends for CGEM. MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures were lower this morning ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Cullinan Therapeutics, Inc. (CGEM) on Thursday reported a loss of $47.6 million in its fourth quarter. The Cambridge, Massachusetts-based company said ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...